查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1379987

胜肽抗生素市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按类型、给药途径、配销通路、地区和竞争细分

Peptide Antibiotics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Type, by Route of Administration, by Distribution Channel, by region, and Competition
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年，全球胜肽类抗生素市场价值达 49 亿美元，预计到 2028 年，复合CAGR将达到 6.35%。肽类抗生素是一类由短链氨基组成的抗菌化合物。酸，蛋白质的组成部分。这些胜肽可以抑制细菌和其他微生物的生长和繁殖，使其能够有效治疗各种感染性疾病。胜肽抗生素与传统的小分子抗生素不同，因为它们由较大的蛋白质样分子组成。肽抗生素由相对较短的氨基酸链组成，通常为几个到几十个氨基酸残基。这些胜肽的结构可以是线性或环状的。肽类抗生素透过多种机制发挥抗菌作用。有些会破坏细菌细胞膜，导致其破裂。另一些则干扰重要的细胞过程，例如蛋白质合成、DNA 复製或细胞壁合成。机制的多样性使得细菌难以产生抗药性。

主要市场驱动因素

市场概况
预测期 2024-2028
2022 年市场规模 49亿美元
2028 年市场规模 71亿美元
2023-2028 年CAGR 6.35%
成长最快的细分市场 可注射
最大的市场 北美洲

肽合成的进展

固相胜肽合成彻底改变了胜肽的生产。它允许将胜肽构建在固体支撑物上，简化纯化并实现自动化。树脂和连接体技术的发展提高了SPPS的速度和效率。肽合成的自动化已成为许多实验室和生产设施的标准。自动化合成仪能够精确控制反应条件和复杂胜肽的合成。 Fmoc（9-芴甲氧基羰基）和Boc（叔丁氧基羰基）保护基的引入使得胜肽合成更通用和高效。基于 Fmoc 的 SPPS 目前是最广泛使用的方法，因为它与自动合成和较温和的去保护条件相容。

胜肽组装策略的进步，例如一锅或多段合成，简化了长肽或复杂胜肽的合成。正交保护基团的开发允许特定官能基的选择性脱保护，从而增强具有挑战性的胜肽的合成。连续流肽合成系统已经出现，能够快速且有效率地生产胜肽。流动化学可以精确控制反应条件，并且可以轻鬆扩大规模以进行大规模合成。天然化学连接和表达蛋白连接等方法可以合成更长、更复杂的胜肽甚至蛋白质片段。这些技术对于生产更大的治疗性胜肽至关重要。固相支持物上胜肽库的高通量筛选透过更有效地识别先导化合物加速了药物发现。色谱和质谱技术的进步改进了合成胜肽的纯化和表征。将胜肽与其他分子（例如脂质、蛋白质或奈米颗粒）缀合的技术扩大了胜肽在药物传递和诊断中的应用。透过各种策略（例如二硫键形成或装订）对胜肽进行环化，可增强其稳定性和生物活性。这一因素将有助于全球肽抗生素市场的发展。

抗生素抗药性上升

当细菌形成抵抗抗生素作用的机制时，就会出现抗生素抗药性，使这些药物在治疗细菌感染方面效果较差或完全无效。这场全球健康危机迫切需要新型创新抗生素。胜肽抗生素通常具有与传统抗生素不同的新颖作用机制。这些机制可以使细菌难以快速产生抗药性，使得胜肽类抗生素在对抗抗药性菌株方面具有重要价值。一些胜肽抗生素具有广谱活性，这意味着它们可以针对多种细菌病原体。在处理各种抗药性细菌引起的感染时，这种多功能性至关重要。肽类抗生素不太可能与现有抗生素产生交叉抗药性。针对传统抗生素的细菌抗药性机制可能对胜肽无效。肽抗生素可以同时针对多种重要的细菌功能，这使得细菌很难透过单一突变产生抗药性。胜肽抗生素通常对细菌细胞具有高度特异性，最大限度地减少对人体细胞的附带损害并降低副作用的风险。

研究人员可以探索涉及胜肽抗生素和传统抗生素的联合疗法，以提高疗效并降低抗药性的可能性。一些胜肽类抗生素已在治疗抗药性感染方面表现出临床有效性，增强了其临床实践价值。正在进行的研究工作重点是发现具有改进特性的新型胜肽抗生素，包括增强效力、稳定性和降低毒性。医疗机构正在实施抗生素管理计划，以确保负责任地使用抗生素，包括在需要时使用胜肽抗生素等新型抗生素。流行病等全球健康威胁的出现凸显了有效抗生素（包括胜肽抗生素）治疗继发性细菌感染的重要性。监管机构意识到迫切需要针对抗药性感染的有效治疗方法，因此愿意简化新型抗生素的审批流程。临床环境中对抗生素，特别是对抗药性病原体有效的抗生素的需求仍然很高，这推动了对胜肽抗生素的市场需求。这项因素将加快全球胜肽抗生素市场的需求。

老年人口不断增加

老化往往伴随着免疫系统减弱，使老年人更容易受到感染。他们罹患肺炎、泌尿道感染和皮肤感染等细菌感染的风险较高，可能需要抗生素治疗，包括胜肽类抗生素。许多老年人患有一种或多种慢性健康状况，例如糖尿病、心血管疾病或呼吸系统疾病。这些情况会增加感染的风险，可能需要抗生素来控製或治疗与这些疾病相关的感染。居住在长期照护机构或疗养院的长者可能面临更高的医疗相关感染风险。胜肽抗生素对于治疗和预防这个弱势族群的感染非常重要。老年人可能会接受手术来解决与年龄相关的健康问题，术后感染是一个问题。在这些情况下，可以使用抗生素，包括胜肽抗生素来预防或治疗。

老年人通常有复杂的医疗保健需求，包括多种药物和合併症。这种复杂性会增加​​药物交互作用的风险，并需要使用抗生素来治疗感染。肺炎和支气管炎等呼吸道感染在老年人中很常见，可能需要抗生素治疗。一些胜肽抗生素已被证明对呼吸道病原体有效。体弱的老年人更有可能住院治疗，因为他们可能会接触抗抗生素的病原体。有效的抗生素，例如胜肽抗生素，对于控制这些感染至关重要。由于不良反应和药物交互作用的风险，因此对老年人谨慎使用抗生素至关重要。具有特定作用机制的胜肽抗生素可能是优选的，以尽量减少潜在的副作用。研究人员越来越多地研究抗生素（包括胜肽抗生素）在老年人群中的安全性和有效性，以确保适当的剂量和治疗指南。随着预期寿命的延长，越来越多的人达到了可能需要抗生素治疗各种感染的年龄，这进一步增加了对抗生素的需求。这项因素将加速全球肽类抗生素市场的需求。

主要市场挑战

开发成本高

肽抗生素的开发始于广泛的研究，以确定有前途的化合物及其作用机制。临床前测试涉及体外和动物研究以评估安全性和有效性。这些早期阶段需要大量资金用于研究人员、实验室设施和动物照护。临床试验是开发过程中至关重要的一步。它们涉及对人体进行严格的测试以评估安全性和有效性。临床试验分为几个阶段，每个阶段都会增加整体成本。 III 期试验涉及大量患者，费用可能特别昂贵。满足美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA) 等机构制定的监管要求是一个成本高且耗时的过程。开发人员必须进行研究并收集大量资料，以证明安全性和有效性，并符合品质标准。扩大胜肽抗生素的生产用于临床试验和最终商业化是一笔巨大的开支。在大规模生产过程中保持一致的品质和纯度至关重要，并且会增加成本。严格的品质控制和保证流程对于确保胜肽抗生素符合安全性和有效性标准至关重要。这些过程需要对专业人员、设备和基础设施进行投资。取得和维护新型胜肽抗生素的专利可能成本高昂，但对于保护研发投资至关重要。临床支持，包括监测病人安全和收集资料，增加了临床试验的成本。持续监控对于确保产品的安全性和有效性至关重要。

有限的目标频谱

许多胜肽抗生素对特定的细菌亚群或特定类型的感染有效。这种有限的目标范围意味着它们可能不适合治疗广泛的细菌感染，包括由目标范围之外的细菌引起的感染。在临床实践中，医疗保健提供者确定引起感染的确切细菌病原体可能具有挑战性。如果肽类抗生素的目标谱较窄，则可能无法覆盖导致感染的特定病原体，从而导致治疗失败。医疗保健提供者必须准确诊断感染细菌，以选择最合适的抗生素。肽类抗生素的标靶光谱有限，可能会导致其在无效的情况下使用不当，从而导致抗药性的产生。为了解决窄标靶的挑战，胜肽抗生素可能需要与其他抗生素合併使用。这会增加治疗方案的复杂性和不良反应的风险。窄谱胜肽抗生素的临床应用可能有限，特别是在由于诊断不确定性或混合感染的可能性而可能优选更广谱抗生素的情况下。肽抗生素市场面临其他抗生素的竞争，其中一些抗生素具有更广泛的活性。这种竞争可能会影响胜肽抗生素的采用，特别是在选择治疗方案时。

主要市场趋势

人们对抗菌肽 (AMP) 的认识不断增强

AMP 是在各种生物体中发现的天然分子，包括人类、动物、植物和微生物。它们来源的多样性为发现具有独特性质的新 AMP 提供了机会。 AMP 通常表现出广泛的抗菌活性，这意味着它们可以针对多种细菌、真菌、病毒，甚至寄生虫。这种多功能性对于对抗各种传染源非常有价值。 AMP 的作用机转与传统抗生素不同，这使得微生物难以快速产生抗药性。这在抗生素抗药性不断上升的背景下尤其重要。有些 AMP 具有免疫调节功能，包括调节宿主免疫反应的能力。此功能有助于控制感染和发炎。 AMP 可与传统抗生素合併使用，以增强其有效性并降低抗药性风险。这种方法正在探索治疗多重抗药性感染。某些 AMP 具有伤口癒合特性，可促进组织修復和再生。它们用于各种医疗应用，包括伤口敷料和护肤产品。製药和生物技术公司正在投资基于 AMP 的疗法的开发和商业化，这进一步推动了人们对该领域的认识和兴趣。在某些情况下，AMP 被认为是传统抗生素的替代品，特别是在治疗由多重抗药性或难以治疗的病原体引起的感染时。

细分市场洞察

类型洞察

2022年，全球胜肽类抗生素市场最大份额由非核醣体合成胜肽类抗生素领域占据，预计未来几年将继续扩大。非核醣体合成胜肽抗生素通常具有独特的作用机制，使其能够有效对抗多种细菌，包括抗生素抗药性菌株。这种多功能性有助于提高它们的受欢迎程度和市场份额。一些非核醣体合成胜肽抗生素在治疗具有挑战性的细菌感染方面表现出很高的临床疗效，从而导致其广泛使用和采用。非核醣体合成胜肽抗生素可能不太容易受到影响传统抗生素的某些抗药性机制的影响，这使得它们在增加抗生素抗药性的背景下很有价值。某些非核醣体合成胜肽抗生素用于专门的医疗环境，例如治疗医疗机构中的特定感染或免疫功能低下的患者。这可以推动对这些产品的需求。

管理途径见解

2022年，全球胜肽抗生素市场最大份额由注射给药途径占据，预计未来几年将继续扩大。通常选择胜肽抗生素的注射製剂，因为它们提供了一种可靠且有效的方式将药物直接输送到血液中。这确保了药物的快速和一致吸收，使其在治疗严重细菌感染方面非常有效。肽抗生素通常用于治疗严重且危及生命的感染，例如败血症、肺炎以及某些类型的皮肤和软组织感染。在这种情况下，优选注射製剂以确保立即发挥治疗作用。由于受控环境和密切监测患者的能力，医院和医疗机构经常使用注射药物。当处理需要及时治疗的危重患者时，这一点尤其重要。

配销通路洞察

2022年，全球肽类抗生素市场最大份额由医院药房部门占据，预计未来几年将继续扩大。肽抗生素通常用于治疗严重且危及生命的感染，这些感染通常需要住院治疗。医院药局在医疗机构内供应和管理这些药物的分配方面发挥着至关重要的作用。医院通常储备多种药物，包括胜肽抗生素等专门抗生素，以满足患者的需求。医院药房设备齐全，可以安全有效地储存和分发这些药物。许多胜肽抗生素透过静脉注射给药，这在医院环境中很常见。医院药房负责配製和製备这些抗生素的静脉注射製剂，确保剂量准确和无菌。

区域洞察

北美地区将在 2022 年主导全球胜肽抗生素市场。北美，尤其是美国，一直是全球医疗保健支出水准最高的地区之一。这笔巨额医疗保健支出用于支持药物（包括胜肽抗生素）的研发、製造和分销。该地区拥有发达的医疗基础设施，包括世界一流的医院、研究机构和製药公司。该基础设施促进了药品的开发、生产和分销。北美是药物研究和创新的中心。它是许多生物技术和製药公司的所在地，这些公司大力投资开发新型药物，包括胜肽抗生素。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球胜肽类抗生素市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依类型（非核醣体合成胜肽抗生素、核醣体合成胜肽抗生素）
    • 依给药途径（注射、口服、局部）
    • 按配销通路（医院药房、网路药房和零售药房）
    • 按公司划分 (2022)
  • 市场地图

第 6 章：亚太地区胜肽类抗生素市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 依给药途径
    • 按配销通路
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国胜肽抗生素
    • 印度胜肽抗生素
    • 澳洲胜肽抗生素
    • 日本胜肽抗生素
    • 韩国胜肽抗生素

第 7 章：欧洲胜肽类抗生素市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 依给药途径
    • 按配销通路
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 8 章：北美胜肽类抗生素市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 依给药途径
    • 按配销通路
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 9 章：南美洲胜肽类抗生素市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 依给药途径
    • 按配销通路
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第10章：中东和非洲胜肽类抗生素市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 依给药途径
    • 按配销通路
    • 按国家/地区
  • MEA：国家分析
    • 南非胜肽抗生素
    • 沙乌地阿拉伯胜肽抗生素
    • 阿联酋胜肽抗生素

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 13 章：全球胜肽抗生素市场：SWOT 分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第 15 章：大环境分析

第16章：竞争格局

  • 辉瑞公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 默克公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 艾伯维公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 葛兰素史克集团公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 山德士国际有限公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 塞利亚製药公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • AuroMedics 製药股份有限公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 葛兰素史克公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
    • SWOT Analysis
  • 梯瓦製药工业股份有限公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
    • SWOT Analysis
  • 诺华公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
    • SWOT Analysis

第 17 章：策略建议

第 18 章：关于我们与免责声明

简介目录
Product Code: 16968

Global Peptide Antibiotics Market has valued at USD 4.90 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 6.35% through 2028. Peptide antibiotics are a class of antimicrobial compounds that are made up of short chains of amino acids, the building blocks of proteins. These peptides can inhibit the growth and reproduction of bacteria and other microorganisms, making them effective in the treatment of various infectious diseases. Peptide antibiotics are distinct from traditional small-molecule antibiotics in that they are composed of larger, protein-like molecules. Peptide antibiotics consist of relatively short chains of amino acids, typically ranging from a few to several dozen amino acid residues. These peptides can be linear or cyclic in structure. Peptide antibiotics exert their antimicrobial effects through a variety of mechanisms. Some disrupt the bacterial cell membrane, causing it to rupture. Others interfere with essential cellular processes, such as protein synthesis, DNA replication, or cell wall synthesis. The diversity of mechanisms makes it challenging for bacteria to develop resistance.

Peptide antibiotics can have broad-spectrum activity, meaning they are effective against a wide range of bacterial species, or narrow-spectrum activity, targeting specific types of bacteria. The specificity of action can vary among different peptide antibiotics. The increasing prevalence of antibiotic-resistant bacteria is a significant driver for the development and use of peptide antibiotics. These antibiotics often have unique mechanisms of action that can overcome resistance. The aging population is more susceptible to infections, making the development and use of effective antibiotics crucial. Peptide antibiotics can be particularly useful in this context. Technological advances in peptide synthesis have made it more cost-effective and efficient to produce peptide antibiotics, contributing to market growth. Healthcare institutions are implementing antibiotic stewardship programs to optimize the use of antibiotics, ensuring they are used responsibly and judiciously. Surgical procedures often require prophylactic antibiotic use to prevent postoperative infections, creating demand for effective antibiotics, including peptide antibiotics.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 4.90 Billion
Market Size 2028USD 7.10 Billion
CAGR 2023-20286.35%
Fastest Growing SegmentInjectable
Largest MarketNorth America

Advancements in Peptide Synthesis

Solid-phase peptide synthesis revolutionized peptide production. It allows peptides to be built on a solid support, simplifying purification, and enabling automation. The development of resin and linker technologies has improved the speed and efficiency of SPPS. Automation of peptide synthesis has become standard in many laboratories and production facilities. Automated synthesizers enable precise control of reaction conditions and the synthesis of complex peptides. The introduction of Fmoc (9-fluorenylmethyloxycarbonyl) and Boc (tert-butyloxycarbonyl) protecting groups has made peptide synthesis more versatile and efficient. Fmoc-based SPPS is now the most widely used method due to its compatibility with automated synthesis and milder deprotection conditions.

Advances in peptide assembly strategies, such as one-pot or multi-segment synthesis, have simplified the synthesis of long or complex peptides. The development of orthogonal protecting groups allows for the selective deprotection of specific functional groups, enhancing the synthesis of challenging peptides. Continuous-flow peptide synthesis systems have emerged, enabling rapid and efficient peptide production. Flow chemistry offers precise control over reaction conditions and can be easily scaled up for large-scale synthesis. Methods like native chemical ligation and expressed protein ligation enable the synthesis of longer and more complex peptides and even protein fragments. These techniques have been crucial in producing larger therapeutic peptides. High-throughput screening of peptide libraries on solid supports has accelerated drug discovery by identifying lead compounds more efficiently. Advances in chromatography and mass spectrometry techniques have improved the purification and characterization of synthetic peptides. Techniques for conjugating peptides to other molecules, such as lipids, proteins, or nanoparticles, have expanded the applications of peptides in drug delivery and diagnostics. Cyclization of peptides through various strategies, such as disulfide bond formation or stapling, enhances their stability and bioactivity. This factor will help in the development of the Global Peptide Antibiotics Market.

Rising Antibiotic Resistance

Antibiotic resistance occurs when bacteria develop mechanisms to withstand the effects of antibiotics, rendering these drugs less effective or completely ineffective in treating bacterial infections. This global health crisis has created a pressing need for new and innovative antibiotics. Peptide antibiotics often have novel mechanisms of action that are distinct from traditional antibiotics. These mechanisms can make it difficult for bacteria to develop resistance quickly, making peptide antibiotics valuable in the fight against drug-resistant strains. Some peptide antibiotics exhibit a broad spectrum of activity, meaning they can target a wide range of bacterial pathogens. This versatility is essential when dealing with infections caused by various resistant bacteria. Peptide antibiotics are less likely to face cross-resistance with existing antibiotics. Bacterial resistance mechanisms that work against conventional antibiotics may not be effective against peptides. Peptide antibiotics can target multiple essential bacterial functions simultaneously, making it challenging for bacteria to develop resistance through single mutations. Peptide antibiotics often have high specificity for bacterial cells, minimizing collateral damage to human cells and reducing the risk of side effects.

Researchers can explore combination therapies that involve peptide antibiotics and traditional antibiotics to enhance efficacy and reduce the likelihood of resistance. Some peptide antibiotics have demonstrated clinical effectiveness in treating drug-resistant infections, reinforcing their value in clinical practice. Ongoing research efforts are focused on discovering new peptide antibiotics with improved properties, including enhanced potency, stability, and reduced toxicity. Healthcare institutions are implementing antibiotic stewardship programs to ensure responsible antibiotic use, including the use of newer antibiotics like peptide antibiotics when needed. The emergence of global health threats, such as pandemics, has highlighted the importance of effective antibiotics, including peptide antibiotics, to treat secondary bacterial infections. Regulatory agencies have shown willingness to streamline the approval process for novel antibiotics, recognizing the urgent need for effective treatments against resistant infections. The demand for antibiotics, especially those effective against resistant pathogens, remains high in clinical settings, contributing to the market demand for peptide antibiotics. This factor will pace up the demand of the Global Peptide Antibiotics Market.

Growing Geriatric Population

Aging is often accompanied by a weakened immune system, making older adults more vulnerable to infections. They are at higher risk for bacterial infections such as pneumonia, urinary tract infections, and skin infections, which may require antibiotic treatment, including peptide antibiotics. Many older adults have one or more chronic health conditions, such as diabetes, cardiovascular disease, or respiratory disorders. These conditions can increase the risk of infections, and antibiotics may be needed to manage or treat infections associated with these diseases. Older adults residing in long-term care facilities or nursing homes may be at higher risk for healthcare-associated infections. Peptide antibiotics can be important for treating and preventing infections in this vulnerable population. Older adults may undergo surgeries to address age-related health issues, and postoperative infections are a concern. Antibiotics, including peptide antibiotics, may be used prophylactically or therapeutically in these cases.

Older adults often have complex healthcare needs, including multiple medications and comorbidities. This complexity can increase the risk of drug interactions and necessitate the use of antibiotics for infections. Respiratory infections, such as pneumonia and bronchitis, are common among older adults and may require antibiotic treatment. Some peptide antibiotics have demonstrated effectiveness against respiratory pathogens. Frail older adults are more likely to experience hospitalizations, where they may be exposed to antibiotic-resistant pathogens. Effective antibiotics, such as peptide antibiotics, are essential in managing these infections. Due to the risk of adverse effects and drug interactions, it's crucial to use antibiotics judiciously in older adults. Peptide antibiotics with specific mechanisms of action may be preferred to minimize potential side effects. Researchers are increasingly studying the safety and efficacy of antibiotics, including peptide antibiotics, in geriatric populations to ensure appropriate dosing and treatment guidelines. As life expectancy increases, more people are reaching an age where they may require antibiotic treatment for various infections, further contributing to the demand for antibiotics. This factor will accelerate the demand of the Global Peptide Antibiotics Market.

Key Market Challenges

High Development Costs

The development of a peptide antibiotic begins with extensive research to identify promising compounds and their mechanisms of action. Preclinical testing involves in vitro and animal studies to assess safety and efficacy. These early stages require substantial funding for research personnel, laboratory facilities, and animal care. Clinical trials are a crucial step in the development process. They involve rigorous testing in human subjects to evaluate safety and effectiveness. Clinical trials are divided into phases, with each phase adding to the overall cost. Phase III trials, which involve large patient populations, can be especially expensive. Meeting regulatory requirements set by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) is a costly and time-consuming process. Developers must conduct studies and gather extensive data to demonstrate safety and efficacy, as well as meet quality standards. Scaling up the production of peptide antibiotics for clinical trials and eventual commercialization is a significant expense. Maintaining consistent quality and purity during large-scale manufacturing is crucial and adds to the cost. Stringent quality control and assurance processes are essential to ensure that peptide antibiotics meet safety and efficacy standards. These processes require investment in specialized personnel, equipment, and infrastructure. Securing and maintaining patents for new peptide antibiotics can be expensive and is crucial for protecting investments in research and development. Clinical support, including monitoring patient safety and collecting data, adds to the cost of clinical trials. Ongoing monitoring is essential to ensure the product's safety profile and efficacy.

Limited Target Spectrum

Many peptide antibiotics are effective against a specific subset of bacteria or a particular type of infection. This limited target spectrum means that they may not be suitable for treating a broad range of bacterial infections, including those caused by bacteria outside their target range. In clinical practice, it can be challenging for healthcare providers to determine the exact bacterial pathogen causing an infection. If a peptide antibiotic has a narrow target spectrum, it may not cover the specific pathogen responsible for the infection, leading to treatment failure. Healthcare providers must accurately diagnose the infecting bacteria to choose the most appropriate antibiotic. The limited target spectrum of peptide antibiotics may lead to their inappropriate use in cases where they are not effective, contributing to the development of resistance. To address the challenge of a narrow target spectrum, peptide antibiotics may need to be used in combination with other antibiotics. This can increase the complexity of treatment regimens and the risk of adverse effects. Peptide antibiotics with a narrow spectrum may have limited clinical applications, particularly in settings where a broader spectrum antibiotic may be preferred due to diagnostic uncertainties or the potential for mixed infections. The peptide antibiotics market faces competition from other antibiotics, some of which have broader spectra of activity. This competition can affect the adoption of peptide antibiotics, particularly when selecting treatment options.

Key Market Trends

Growing Awareness of Antimicrobial Peptides (AMPs)

AMPs are naturally occurring molecules found in various organisms, including humans, animals, plants, and microorganisms. Their diversity in sources presents opportunities for the discovery of new AMPs with unique properties. AMPs typically exhibit a broad spectrum of antimicrobial activity, meaning they can target a wide range of bacteria, fungi, viruses, and even parasites. This versatility is valuable in combating various infectious agents. AMPs have mechanisms of action that differ from traditional antibiotics, making it challenging for microorganisms to develop resistance quickly. This is particularly important in the context of rising antibiotic resistance. Some AMPs possess immunomodulatory functions, including the ability to modulate the host's immune response. This feature can be beneficial in managing infections and inflammation. AMPs can be used in combination with traditional antibiotics to enhance their effectiveness and reduce the risk of resistance. This approach is being explored in the treatment of multidrug-resistant infections. Certain AMPs have wound-healing properties, promoting tissue repair and regeneration. They are used in various medical applications, including wound dressings and skincare products. Pharmaceutical and biotechnology companies are investing in the development and commercialization of AMP-based therapies, which is driving further awareness and interest in this field. In some cases, AMPs are considered an alternative to traditional antibiotics, especially when treating infections caused by multidrug-resistant or difficult-to-treat pathogens.

Segmental Insights

Type Insights

In 2022, the Global Peptide Antibiotics Market largest share was held by non-ribosomal synthesized peptide antibiotics segment and is predicted to continue expanding over the coming years. Non-ribosomal synthesized peptide antibiotics often have unique mechanisms of action that make them effective against a broad spectrum of bacteria, including antibiotic-resistant strains. This versatility can contribute to their popularity and market share. Some non-ribosomal synthesized peptide antibiotics have demonstrated high clinical efficacy in treating challenging bacterial infections, leading to their widespread use and adoption. Non-ribosomal synthesized peptide antibiotics may be less susceptible to certain resistance mechanisms that affect traditional antibiotics, making them valuable in the context of increasing antibiotic resistance. Certain non-ribosomal synthesized peptide antibiotics are used in specialized medical settings, such as the treatment of specific infections in healthcare settings or immunocompromised patients. This can drive demand for these products.

Route of Administration Insights

In 2022, the Global Peptide Antibiotics Market largest share was held by injectable route of administration segment and is predicted to continue expanding over the coming years. Injectable formulations of peptide antibiotics are often chosen because they offer a reliable and efficient way to deliver the medication directly into the bloodstream. This ensures rapid and consistent drug absorption, making them highly effective in treating serious bacterial infections. Peptide antibiotics are frequently used to treat severe and life-threatening infections, such as sepsis, pneumonia, and certain types of skin and soft tissue infections. In such cases, injectable formulations are preferred to ensure immediate therapeutic action. Hospitals and healthcare facilities often administer injectable medications due to the controlled environment and the ability to closely monitor patients. This is especially important when dealing with critically ill patients who require prompt treatment.

Distribution Channel Insights

In 2022, the Global Peptide Antibiotics Market largest share was held by hospital pharmacies segment in the forecast period and is predicted to continue expanding over the coming years. Peptide antibiotics are often used to treat serious and life-threatening infections, which frequently require hospitalization. Hospital pharmacies play a crucial role in supplying and managing the distribution of these medications within healthcare facilities. Hospitals typically stock a wide range of medications, including specialized antibiotics like peptide antibiotics, to meet the needs of their patients. Hospital pharmacies are well-equipped to store and dispense these medications safely and efficiently. Many peptide antibiotics are administered intravenously, which is common in hospital settings. Hospital pharmacies are responsible for compounding and preparing IV formulations of these antibiotics, ensuring accurate dosing and sterility.

Regional Insights

The North America region dominates the Global Peptide Antibiotics Market in 2022. North America, particularly the United States, has historically had one of the highest healthcare expenditure levels globally. This substantial healthcare spending supports research and development, manufacturing, and distribution of pharmaceuticals, including peptide antibiotics. The region boasts a well-developed healthcare infrastructure, including world-class hospitals, research institutions, and pharmaceutical companies. This infrastructure facilitates the development, production, and distribution of pharmaceutical products. North America is a hub for pharmaceutical research and innovation. It is home to numerous biotechnology and pharmaceutical companies that invest heavily in developing novel medications, including peptide antibiotics.

Key Market Players

  • Pfizer Inc.
  • Merck & Co., Inc.
  • AbbVie Inc
  • GSK Group of Companies
  • Sandoz International GmbH
  • Novartis AG
  • Xellia Pharmaceuticals
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • AuroMedics Pharma LLC

Report Scope:

In this report, the Global Peptide Antibiotics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peptide Antibiotics Market, By Type:

  • Non-Ribosomal Synthesized Peptide Antibiotics
  • Ribosomal Synthesized Peptide Antibiotics

Peptide Antibiotics Market, By Route of Administration:

  • Injectable
  • Oral
  • Topical

Peptide Antibiotics Market, By Distribution Channel:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Global Peptide Antibiotics Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Peptide Antibiotics Market.

Available Customizations:

  • Global Peptide Antibiotics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Peptide Antibiotics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Non-Ribosomal Synthesized Peptide Antibiotics, Ribosomal Synthesized Peptide Antibiotics)
    • 5.2.2. By Route of Administration (Injectable, Oral, Topical)
    • 5.2.3. By Distribution Channel (Hospital Pharmacy, Online Pharmacy & Retail Pharmacy)
    • 5.2.4. By Company (2022)
  • 5.3. Market Map

6. Asia Pacific Peptide Antibiotics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Peptide Antibiotics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. India Peptide Antibiotics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Australia Peptide Antibiotics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel
    • 6.3.4. Japan Peptide Antibiotics Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Type
        • 6.3.4.2.2. By Route of Administration
        • 6.3.4.2.3. By Distribution Channel
    • 6.3.5. South Korea Peptide Antibiotics Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Type
        • 6.3.5.2.2. By Route of Administration
        • 6.3.5.2.3. By Distribution Channel

7. Europe Peptide Antibiotics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Peptide Antibiotics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Germany Peptide Antibiotics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Spain Peptide Antibiotics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Peptide Antibiotics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. United Kingdom Peptide Antibiotics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. North America Peptide Antibiotics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Peptide Antibiotics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Mexico Peptide Antibiotics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Canada Peptide Antibiotics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel

9. South America Peptide Antibiotics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Peptide Antibiotics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Peptide Antibiotics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Peptide Antibiotics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Peptide Antibiotics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Peptide Antibiotics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Peptide Antibiotics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. UAE Peptide Antibiotics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Peptide Antibiotics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Pfizer Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Merck & Co., Inc.
    • 16.2.1. Business Overview
    • 16.2.2. Company Snapshot
    • 16.2.3. Products & Services
    • 16.2.4. Financials (In case of listed companies)
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. AbbVie Inc
    • 16.3.1. Business Overview
    • 16.3.2. Company Snapshot
    • 16.3.3. Products & Services
    • 16.3.4. Financials (In case of listed companies)
    • 16.3.5. Recent Developments
    • 16.3.6. SWOT Analysis
  • 16.4. GSK Group of Companies
    • 16.4.1. Business Overview
    • 16.4.2. Company Snapshot
    • 16.4.3. Products & Services
    • 16.4.4. Financials (In case of listed companies)
    • 16.4.5. Recent Developments
    • 16.4.6. SWOT Analysis
  • 16.5. Sandoz International GmbH
    • 16.5.1. Business Overview
    • 16.5.2. Company Snapshot
    • 16.5.3. Products & Services
    • 16.5.4. Financials (In case of listed companies)
    • 16.5.5. Recent Developments
    • 16.5.6. SWOT Analysis
  • 16.6. Xellia Pharmaceuticals
    • 16.6.1. Business Overview
    • 16.6.2. Company Snapshot
    • 16.6.3. Products & Services
    • 16.6.4. Financials (In case of listed companies)
    • 16.6.5. Recent Developments
    • 16.6.6. SWOT Analysis
  • 16.7. AuroMedics Pharma LLC
    • 16.7.1. Business Overview
    • 16.7.2. Company Snapshot
    • 16.7.3. Products & Services
    • 16.7.4. Financials (In case of listed companies)
    • 16.7.5. Recent Developments
    • 16.7.6. SWOT Analysis
  • 16.8. GlaxoSmithKline plc
    • 16.8.1. Business Overview
    • 16.8.2. Company Snapshot
    • 16.8.3. Products & Services
    • 16.8.4. Financials (In case of listed companies)
    • 16.8.5. Recent Developments
    • 16.8.6. SWOT Analysis
    • 16.8.7. SWOT Analysis
  • 16.9. Teva Pharmaceutical Industries Ltd.
    • 16.9.1. Business Overview
    • 16.9.2. Company Snapshot
    • 16.9.3. Products & Services
    • 16.9.4. Financials (In case of listed companies)
    • 16.9.5. Recent Developments
    • 16.9.6. SWOT Analysis
    • 16.9.7. SWOT Analysis
  • 16.10. Novartis AG
    • 16.10.1. Business Overview
    • 16.10.2. Company Snapshot
    • 16.10.3. Products & Services
    • 16.10.4. Financials (In case of listed companies)
    • 16.10.5. Recent Developments
    • 16.10.6. SWOT Analysis
    • 16.10.7. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer